Description du projet
Une technologie innovante pour la stratification des tumeurs chez les patients atteints de cancer du poumon
Le cancer du poumon est la principale cause de décès chez les patients atteints de cancer dans le monde. Le cancer du poumon non à petites cellules (CPNPC) compte pour 85 % de tous les cas de cancer du poumon. Cependant, la stratégie de traitement actuelle est principalement basée sur le système de stadification de l’opérabilité chirurgicale qui ne fournit pas un pronostic précis. L’hétérogénéité entre les patients et les tumeurs représente un défi clinique majeur. Theragnostic, aux Pays-Bas, a mis au point une nouvelle technologie qui permet de stratifier les patients à l’aide de biomarqueurs d’imagerie et de l’imagerie de routine CT et PET. Le projet RAIL, financé par l’UE, a pour ambition de valider un biomarqueur d’imagerie de niveau I multisite et son application pour fournir des informations pronostiques plus précises. Cela permettra de personnaliser le traitement des patients atteints de CPNPC.
Objectif
Lung cancer is the most common cause of death from cancer worldwide with 1.59 million deaths annually. It also places the highest economic burden of all cancers on the EU with EUR 18.8 billion. Non-small cell lung cancer (NSCLC) comprises 85% of all lung cancer cases. The current clinical routine to guide treatment for NSCLC patients is primarily based on the TNM staging system founded in 1958, mainly to look at surgical operability. However, TNM-based evaluation, nor doctors prediction do not provide an accurate prognosis. The heterogeneity between patients (inter-patient), tumours (inter-tumour) and even within one tumour (intra-tumour) underlies these highly variable prognosis and presents a major clinical challenge.
There is a lack of easy to perform, ‘actionable’ biomarkers to stratify NSCLC patients which results in i) under-treatment in 20% of NSCLC patients leading to disease progression and ultimately death, ii) over-treatment in 30% of NSCLC patients which reduces the quality of life of patients and places an economic burden on the healthcare system and iii) ineffective clinical trial design, due to lack of optimal stratification, which requires very large, costly clinical trials to be performed in order to bring new therapeutic strategies to the market.
ptTheragnostic has developed breakthrough technology, called “Radiomics”, which was recently published in Nature Communications, which enables patient stratification through the use of imaging biomarkers acquired from routine CT & PET imaging (see animation on www.pttheragnostic.com). In Radiomics for lung cancer (RAIL) we will validate and qualify a multi-site level I imaging biomarker together with a ready-to-use application to deliver more accurate prognostic information, personalise treatment for NSCLC patients, reduce healthcare costs by EUR 500+ million and enable efficient clinical trial design.
Champ scientifique
- natural sciencescomputer and information sciencessoftware
- medical and health sciencesclinical medicineoncologylung cancer
- medical and health sciencesclinical medicineradiologynuclear medicine
- engineering and technologyelectrical engineering, electronic engineering, information engineeringinformation engineeringtelecommunicationsmobile phones
Programme(s)
Thème(s)
Régime de financement
SME-2 - SME instrument phase 2Coordinateur
6229 EV Maastricht
Pays-Bas
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.